Fluent Perla CBD Vape Cartridge – 300mg
Relief Can Be a Precious Thing – Perla is an Indica-dominant hybrid produced through a cross of Cannabis sativa and Cannabis indica plants and has a ratio of 1:40 THC:CBD. As our first in-house developed strain, Perla has demonstrated a consistently robust cannabinoid profile through numerous laboratory analyses, exhibiting record-breaking quantities of CBD above 29%. The terpene content is rich with an abundance of Linalool and Pinene, providing well-balanced effects in both the body and mind. Perla is a whole-plant product that contains concentrations of CBD, THC (<.8%), and a full range of other natural components found in cannabis including terpenes, flavonoids and other cannabinoids that contribute to the medicinal properties of cannabis.
Current medical literature supports the use of CBD rich products for the treatment of pediatric and drug-resistant epilepsy (in combination with other antiepileptic medications) and chronic neuropathic pain.
CBD Content: Approximately 97.6%
THC Content: Approximately <.8%
THC to CBD Ratio: 40:1
Dosing Units: Each 300 mg cartridge contains 1 mg CBD/inhalation
Total Doses: Approximately 300 inhalations per cartridge (1ml)
Sold By: Fluent
Leave Your Review: Write A Review
Out of stock
“Vaping” is short for “vaporization”. Effects are felt immediately and unlike smoking, no combustion or burning takes place. Portable vaporizers are very discreet, as vapor dissipates quickly with minimal odor.
Patients are recommended to initiate treatment on the evening of Day 1 with 1-3 inhalation sessions. Each session consists of 1-2 draws that are relatively shallow (1-3 seconds) and held for about 5 seconds before exhaling. After 5-10 minutes, patients reassess symptoms. If symptoms have improved or subsided, no additional sessions are needed and patients take the next dose on the morning of Day 2.
Perla® is contraindicated in patients:
• with hypersensitivity to cannabinoids (e.g., THC or CBD) or to any of the inert ingredients in Perla®;
• with a significant history of cardiovascular disease;
• with an active or previous psychotic or active mood or anxiety disorder; and
• who are pregnant, planning to become pregnant, or are breastfeeding.